Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
He has 29+ years’ comprehensive experience in world-class Formulations and API (for US and EU requirements) mainly related to injectables
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Karkinos is in the business of providing technology-driven, innovative solutions for the early detection, diagnosis, and management of cancer.
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
JCI accreditation is recognized globally
Subscribe To Our Newsletter & Stay Updated
